Marc P. Bonaca, MD, MPH

Clinical Update

Rivaroxaban After Lower-Extremity Revascularization: The VOYAGER PAD Trial

05/20/2023

The phase 3 VOYAGER PAD trial demonstrated the benefit of rivaroxaban (Xarelto, Janssen Pharmaceutical Companies of Johnson & Johnson) (2.5 mg twice daily + aspirin 100 mg once daily) in reducing severe vascular events in peripheral artery...

The phase 3 VOYAGER PAD trial...

05/20/2023

Cath Lab Digest

Featured Webinar

Implementing ERAS Protocols Throughout Patient Peri-Op Journey: Reductions in Complications

Upcoming Events

November 13 ⁠–⁠ November 16

November 13 ⁠–⁠ November 16

November 14 ⁠–⁠ November 15

November 23 ⁠–⁠ November 24

December 4 ⁠–⁠ December 5

Great Debates & Updates in Diabetic Foot

December 6 ⁠–⁠ December 7

December 9 ⁠–⁠ December 11

December 12 ⁠–⁠ December 13

December 14 ⁠–⁠ December 15

See Full Calendar

Marc P. Bonaca, MD, MPH

Featured Webinar

Upcoming Events

Specialties

Events

Year Round Education

HMP Global Products